E
Eric Sicard
Researcher at Algorithme Pharma
Publications - 24
Citations - 751
Eric Sicard is an academic researcher from Algorithme Pharma. The author has contributed to research in topics: Cmax & Bioequivalence. The author has an hindex of 11, co-authored 23 publications receiving 610 citations.
Papers
More filters
Journal ArticleDOI
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
E.J. Gane,Young-Suk Lim,Stuart C. Gordon,Kumar Visvanathan,Eric Sicard,Richard N. Fedorak,Stuart K. Roberts,Benedetta Massetto,Zhishen Ye,Stefan Pflanz,Kimberly L. Garrison,Anuj Gaggar,G. Mani Subramanian,John G. McHutchison,Shyamasundaran Kottilil,B. Freilich,Carla S. Coffin,Wendy Cheng,Yoon Jun Kim +18 more
TL;DR: Oral GS-9620 was safe, well tolerated, and associated with induction of peripheral ISG15 production in the absence of significant systemic IFN-alpha levels or related symptoms in patients with chronic hepatitis B.
Journal ArticleDOI
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Kosh Agarwal,Scott Fung,Tuan T. Nguyen,Wendy Cheng,Eric Sicard,Stephen D. Ryder,John F. Flaherty,Eileen Lawson,Sally Zhao,G. Mani Subramanian,John G. McHutchison,Edward Gane,Graham R. Foster +12 more
TL;DR: Tenofovir alafenamide 25 mg was safe and well tolerated; declines in HBV DNA were similar to ten ofovir disoproxil fumarate at all doses evaluated.
Journal ArticleDOI
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers
Martin Bitzan,Ruth Poole,Mariam Mehran,Eric Sicard,Catherine Brockus,Claire Thuning-Roberson,Marc Riviere +6 more
TL;DR: Evaluated chimeric monoclonal antibodies against Stx 1 and 2, given as individual or combined short intravenous infusions, are well tolerated and form the basis for future safety and efficacy trials with patients with STEC infections to ameliorate or prevent HUS and other complications.
Journal ArticleDOI
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
John F. Kokai-Kun,Tracey Roberts,Olivia Coughlin,Eric Sicard,Marianne Rufiange,Richard N. Fedorak,Christian Carter,Marijke H. Adams,James Longstreth,Heidi Whalen,Joseph Sliman +10 more
TL;DR: The two phase 2a clinical studies described here were performed to confirm the mechanism of action of ribaxamase, degradation of β-lactam antibiotics in the human intestine, and were therefore conducted in subjects with functioning ileostomies to allow serial sampling of their intestinal chyme.
Journal ArticleDOI
Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects.
Luís Pereira de Almeida,Teresa G. Nunes,Eric Sicard,José-Francisco Rocha,Amílcar Falcão,Jean-Sébastien Brunet,Marc Lefebvre,Patrício Soares-da-Silva,Patrício Soares-da-Silva +8 more
TL;DR: A pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects and the effects of these drugs on brain structure and function is studied.